RU2016107610A - Фармацевтическая композиция - Google Patents
Фармацевтическая композиция Download PDFInfo
- Publication number
- RU2016107610A RU2016107610A RU2016107610A RU2016107610A RU2016107610A RU 2016107610 A RU2016107610 A RU 2016107610A RU 2016107610 A RU2016107610 A RU 2016107610A RU 2016107610 A RU2016107610 A RU 2016107610A RU 2016107610 A RU2016107610 A RU 2016107610A
- Authority
- RU
- Russia
- Prior art keywords
- insulin
- range
- derivative
- isoelectric point
- metabolite
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 84
- 239000004026 insulin derivative Substances 0.000 claims 41
- 102000004877 Insulin Human genes 0.000 claims 31
- 108090001061 Insulin Proteins 0.000 claims 31
- 229940125396 insulin Drugs 0.000 claims 31
- 239000002207 metabolite Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 108010073961 Insulin Aspart Proteins 0.000 claims 9
- 229960004717 insulin aspart Drugs 0.000 claims 9
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 108010057186 Insulin Glargine Proteins 0.000 claims 5
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 5
- 229960002869 insulin glargine Drugs 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 108010065920 Insulin Lispro Proteins 0.000 claims 4
- 102000007327 Protamines Human genes 0.000 claims 4
- 108010007568 Protamines Proteins 0.000 claims 4
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 4
- 229940048914 protamine Drugs 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 108010081368 Isophane Insulin Proteins 0.000 claims 2
- 102000005237 Isophane Insulin Human genes 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 230000000422 nocturnal effect Effects 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 1
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 1
- 229940100066 Long-acting insulin Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3124/MUM/2013 | 2013-09-30 | ||
| IN3124MU2013 IN2013MU03124A (https=) | 2013-09-30 | 2014-09-29 | |
| PCT/IB2014/064922 WO2015044922A1 (en) | 2013-09-30 | 2014-09-29 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016107610A true RU2016107610A (ru) | 2017-11-03 |
Family
ID=51903957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016107610A RU2016107610A (ru) | 2013-09-30 | 2014-09-29 | Фармацевтическая композиция |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160271226A1 (https=) |
| EP (1) | EP3052114A1 (https=) |
| JP (1) | JP2016531847A (https=) |
| CN (1) | CN105579052A (https=) |
| AU (1) | AU2014326181A1 (https=) |
| BR (1) | BR112016006963A2 (https=) |
| IN (1) | IN2013MU03124A (https=) |
| RU (1) | RU2016107610A (https=) |
| SG (1) | SG11201601477VA (https=) |
| WO (1) | WO2015044922A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3419649B1 (en) * | 2016-02-25 | 2025-04-09 | Wockhardt Limited | Stable pharmaceutical compositions comprising insulin glargine and insulin aspart and methods of preparation thereof |
| CN106729639B (zh) * | 2017-01-10 | 2018-02-27 | 鲁南制药集团股份有限公司 | 一种甘精胰岛素注射液及其制备方法 |
| DK4019039T3 (da) | 2017-07-27 | 2024-01-15 | Adocia | Sammensætninger i form af en injicerbar vandig opløsning, som omfatter mindst et humant insulin A21G og en glucagonundertrykker med prandial virkning |
| AU2020324961A1 (en) * | 2019-08-02 | 2022-03-24 | Case Western Reserve University | Premixed ultra-stable single-chain insulin analogue formulations |
| EP3915571A1 (en) * | 2020-05-29 | 2021-12-01 | Adocia | Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action |
| EP3915572A1 (en) * | 2020-05-29 | 2021-12-01 | Adocia | Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3316363A1 (de) | 1983-05-05 | 1984-11-08 | Deutsche Babcock Anlagen Ag, 4200 Oberhausen | Walzenrost fuer muellverbrennungsanlagen |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
| PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| EP1506003A1 (en) * | 2002-05-07 | 2005-02-16 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
| CN101237854B (zh) * | 2005-05-23 | 2013-03-27 | Sdg公司 | 将胰岛素输送到哺乳动物的脂构建体 |
| WO2006127361A2 (en) * | 2005-05-23 | 2006-11-30 | Sdg, Inc. | Lipid construct for delivery of insulin to a mammal |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| WO2007041481A1 (en) | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| CN101454019A (zh) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
| WO2007121256A2 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| WO2009021956A2 (en) | 2007-08-13 | 2009-02-19 | Novo Nordisk A/S | Rapid acting insulin analogues |
| JP5710253B2 (ja) | 2007-08-13 | 2015-04-30 | ノボ・ノルデイスク・エー／エス | 速効型インスリンアナログ |
| WO2011094632A1 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | Method for administration of insulin and pharmaceutical composition thereof |
| JP2013545782A (ja) * | 2010-12-14 | 2013-12-26 | ノヴォ ノルディスク アー／エス | 長時間作用型インスリンと組み合わせた速効型インスリン |
| JP5950477B2 (ja) | 2011-08-10 | 2016-07-13 | アドシア | 少なくとも１種の基礎インスリンの注射溶液 |
-
2014
- 2014-09-29 US US15/021,693 patent/US20160271226A1/en not_active Abandoned
- 2014-09-29 IN IN3124MU2013 patent/IN2013MU03124A/en unknown
- 2014-09-29 AU AU2014326181A patent/AU2014326181A1/en not_active Abandoned
- 2014-09-29 WO PCT/IB2014/064922 patent/WO2015044922A1/en not_active Ceased
- 2014-09-29 SG SG11201601477VA patent/SG11201601477VA/en unknown
- 2014-09-29 BR BR112016006963A patent/BR112016006963A2/pt not_active Application Discontinuation
- 2014-09-29 EP EP14799538.5A patent/EP3052114A1/en not_active Withdrawn
- 2014-09-29 JP JP2016515453A patent/JP2016531847A/ja active Pending
- 2014-09-29 RU RU2016107610A patent/RU2016107610A/ru unknown
- 2014-09-29 CN CN201480053586.6A patent/CN105579052A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IN2013MU03124A (https=) | 2015-07-31 |
| EP3052114A1 (en) | 2016-08-10 |
| WO2015044922A1 (en) | 2015-04-02 |
| BR112016006963A2 (pt) | 2017-08-01 |
| CN105579052A (zh) | 2016-05-11 |
| JP2016531847A (ja) | 2016-10-13 |
| US20160271226A1 (en) | 2016-09-22 |
| SG11201601477VA (en) | 2016-04-28 |
| AU2014326181A1 (en) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016107610A (ru) | Фармацевтическая композиция | |
| ES2365410T3 (es) | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| JP2018138578A5 (https=) | ||
| FI2571517T4 (fi) | Insuliinien pitkävaikutteisia formulaatioita | |
| JP2016539921A5 (https=) | ||
| HRP20190777T1 (hr) | Brzodjelujući pripravci inzulina | |
| AR077455A1 (es) | Preparaciones insulinicas de accion lenta | |
| JP2011241213A5 (https=) | ||
| JP2010525033A5 (https=) | ||
| RU2016132340A (ru) | Стабилизированные фармацевтические составы на основе инсулина аспарта | |
| PH12012501135A1 (en) | Insulin analogues with chlorinated amino acids | |
| JP2017519018A5 (https=) | ||
| EA028572B1 (ru) | Стабильная композиция для парентеральной инъекции и способы ее получения и использования | |
| JP2016532698A (ja) | インスリン分泌性ペプチドの安定な水性非経口医薬組成物 | |
| EP4613284A3 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| JP2018528242A (ja) | 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 | |
| Ryou et al. | Pyruvate-enriched cardioplegia suppresses cardiopulmonary bypass-induced myocardial inflammation | |
| JP2020527784A (ja) | 低血糖の治療に関する方法および医学的使用 | |
| Navati et al. | Reducing ischemia/reperfusion injury by the targeted delivery of nitric oxide from magnetic-field-induced localization of S-nitrosothiol-coated paramagnetic nanoparticles | |
| AR074820A1 (es) | Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa | |
| FR3043557A1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| Miao et al. | Dual pH/ROS-responsive carbon dot–based microneedles for biofilm disruption and diabetic wound regeneration | |
| EA201491841A1 (ru) | Состав эсмолола для парентерального введения | |
| JP2016505601A (ja) | 医薬組成物 |